Tarsus Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Tarsus Pharmaceuticals

25/02/2025 14:32

Tarsus Pharmaceuticals Inc TARS.OQ reported a quarterly adjusted loss of 60 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.31.  The mean expectation of nine analysts for the quarter was for a loss of 74 cents per share. Wall Street expected results to range from $-1.04 to -43 cents per share.

Revenue rose 407.9% to $66.41 million from a year ago; analysts expected $58.33 million.

Tarsus Pharmaceuticals Inc's reported EPS for the quarter was a loss of 60 cents​.

The company reported a quarterly loss of $23.11 million.

Tarsus Pharmaceuticals Inc shares had fallen by 17.8% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 4% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is $72.50

This summary was machine generated from LSEG data February 25 at 02:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.74
-0.60
Beat
Sep. 30 2024
-0.97
-0.61
Beat
Jun. 30 2024
-0.92
-0.88
Beat
Mar. 31 2024
-1.20
-1.01
Beat